A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease

References

• Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008;134–141.
   PubMedGoogle Scholar
• Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374–384.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389–401.
   PubMed Web of Science ®Google Scholar
• Baird K, Steinberg SM, Grkovic L, et al. National institutes of health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant. 2013;19:632–639.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium. Blood. 2011a;117:4651–4657.
   Google Scholar
• Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–414.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European society for blood and marrow transplant activity survey report. Bone Marrow Transplant. 2017;52:811–817.
   PubMed Web of Science ®Google Scholar
• Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2015b;21:266–274.
   Google Scholar
• Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol. 2012;158:46–61.
   PubMed Web of Science ®Google Scholar
• Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366–378.
   PubMedGoogle Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Graze PR, Gale RP. Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med. 1979;66:611–620.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Labopin M, Iacobelli S. Statistical guidelines for EBMT. [ cited 2018 Jan]. Available from: https://portal.ebmt.org/sites/clint2/clint/Documents/StatGuidelines_oct2003.pdf
   Google Scholar
• Rychetnik L, Hawe P, Waters E, et al. A glossary for evidence based public health. J Epidemiol Community Health. 2004;58:538–545.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.
   PubMed Web of Science ®Google Scholar
• Detrait M, Morisset S, De Latour RP, et al. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2015;50:253.
   PubMedGoogle Scholar
• Mo X, Xu L, Zhang X, et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant. 2015;50:127.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Tsai H-L, Bolaños-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817–3827.
   PubMed Web of Science ®Google Scholar
• Hamad N, Shanavas M, Michelis FV, et al. Mycophenolate‐based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative‐related donor stem cell transplantation. Am J Hematol. 2015;90:392–399.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28:2859–2867.
   PubMed Web of Science ®Google Scholar
• Pérez-Simón JA, Encinas C, Silva F, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14:1163–1171.
   PubMed Web of Science ®Google Scholar
• Slack JL, Dueck AC, Fauble VD, et al. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transplant. 2013;19(8):1167–1174.
   PubMed Web of Science ®Google Scholar
• Kröger N, Solano C, Wolschke, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;7(374):43–53.
   Google Scholar
• Al-Kadhimi Z, Gul Z, Chen W, et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biol Blood Marrow Transplant. 2014;20:979–985.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore CA, et al. T-cell–replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–1316.
   PubMed Web of Science ®Google Scholar
• Gazourian L, Rogers AJ, Ibanga R, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89:404–409.
   PubMed Web of Science ®Google Scholar
• Granier C, Biard L, Masson E, et al. Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10‐HLA matched donors and cord blood. Am J Hematol. 2015;90:897–903.
   PubMed Web of Science ®Google Scholar
• Ponce DM, Eapen M, Sparapani R, et al. In vivo T cell depletion with myeloablative regimens on outcomes after cord blood transplantation for acute lymphoblastic leukemia in children. Biol Blood Marrow Transplant. 2015;21:2173–2179.
   PubMed Web of Science ®Google Scholar
• Delbos F, Barhoumi W, Cabanne L, et al. Donor immunization against human leukocyte class II antigens is a risk factor for graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:292–299.
   PubMed Web of Science ®Google Scholar
• Duque-Afonso J, Ihorst G, Wäsch R, et al. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:1098–1103.
   PubMed Web of Science ®Google Scholar
• von Bahr L, Blennow O, Alm J, et al. Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50:1217–1223.
   PubMed Web of Science ®Google Scholar
• Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012;119:4083–4090.
   PubMed Web of Science ®Google Scholar
• McClune BL, Ahn KW, Wang H-L, et al. Allotransplantation for patients age≥ 40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014;20:960–968.
   PubMed Web of Science ®Google Scholar
• Kuzmina Z, Eder S, Böhm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746.
   PubMed Web of Science ®Google Scholar
• Arai Y, Takeda J, Aoki K, et al. Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood. 2015a;126:415–422.
   PubMed Web of Science ®Google Scholar
• Gomez E, Dulery R, Langlois C, et al. Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. Bone Marrow Transplant. 2014;49:1492–1497.
   PubMedGoogle Scholar
• Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:449–455.
   PubMedGoogle Scholar
• Hagen P, Wagner J, DeFor T, et al. The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. Bone Marrow Transplant. 2014;49:1498.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Sanz G, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891.
   PubMed Web of Science ®Google Scholar
• McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–1887.
   PubMed Web of Science ®Google Scholar
• Terwey T, Le Duc T, Hemmati P, et al. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol. 2013;24:1363–1370.
   PubMed Web of Science ®Google Scholar
• Vasu S, Geyer S, Bingman A, et al. Granulocyte colony-stimulating factor–mobilized allografts contain activated immune cell subsets associated with risk of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:658–668.
   PubMed Web of Science ®Google Scholar
• Kheav VD, Busson M, Scieux C, et al. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99:1860–1867.
   PubMed Web of Science ®Google Scholar
• Omer AK, Weisdorf DJ, Lazaryan A, et al. Late acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:879–883.
   PubMedGoogle Scholar
• Uhlving HH, Bang CL, Christensen IJ, et al. Lung function after allogeneic hematopoietic stem cell transplantation in children: a longitudinal study in a population-based cohort. Biol Blood Marrow Transplant. 2013;19:1348–1354.
   PubMedGoogle Scholar
• Atta EH, de Oliveira DC, Bouzas LF, et al. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation. PLoS One. 2014;9:e107155.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors. Biol Blood Marrow Transplant. 2016;22:125–133.
   PubMed Web of Science ®Google Scholar
• Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant. 2007;13:1145–1152.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:1380–1384.
   PubMed Web of Science ®Google Scholar
• Inagaki J, Moritake H, Nishikawa T, et al. Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by national institutes of health consensus criteria after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1973–1980.
   PubMedGoogle Scholar
• Busca A, Passera R, Pini M, et al. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. Am J Hematol. 2015;90:E117–21.
   PubMed Web of Science ®Google Scholar
• Sayehmiri K, Carson KV, Bakhtiyari S, et al. Effects of aGVHD and cGVHD according to relapse status on survival rate in patients with acute lymphocytic leukemia. Hematology. 2014;19:441–447.
   PubMed Web of Science ®Google Scholar
• Cho B-S, Lee S-E, Song -H-H, et al. Graft-versus-tumor effect according to type of graft-versus-host disease defined by national institutes of health consensus criteria and associated outcomes. Biol Blood Marrow Transplant. 2012;18:1136–1143.
   PubMed Web of Science ®Google Scholar
• Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012;31:1530–1538.
   Web of Science ®Google Scholar
• DeCook L, Thoma M, Huneke T, et al. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transplant. 2013;48(708):708–714.
   PubMedGoogle Scholar
• Mo XD, Tang BL, Zhang XH, et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. Int J Cancer. 2016a;139:2106–2115.
   PubMed Web of Science ®Google Scholar
• Moon JH, Sohn SK1, Lambie A, et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant. 2014;20:556–563.
   PubMed Web of Science ®Google Scholar
• Saillard C, Crocchiolo R, Furst S, et al. National institutes of health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma. 2014;55:1106–1112.
   PubMed Web of Science ®Google Scholar
• Uhm J, Hamad N, Shin EM, et al. Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1751–1757.
   PubMedGoogle Scholar
• Pidala J, Kim J, Anasetti C, et al. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011b;46:641–649.
   PubMed Web of Science ®Google Scholar
• Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24:1852–1858.
   PubMed Web of Science ®Google Scholar
• Hemmati PG, Terwey TH, Na IK, et al. Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome. Eur J Haematol. 2015;95:498–506.
   PubMed Web of Science ®Google Scholar
• Kagoya Y, Seo S, Nannya Y, et al. Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. Clin Transplant. 2012;26:E168–75.
   PubMed Web of Science ®Google Scholar
• Moon J-H, Lee S-J, Kim J-G, et al. Clinical significance of autoantibody expression in allogeneic stem-cell recipients. Transplantation. 2009;88:242–250.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Nishida T, Asano-Mori Y, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan society for hematopoietic cell transplantation transplantation-related complication working group. Biol Blood Marrow Transplant. 2015;21:2008–2016.
   PubMed Web of Science ®Google Scholar
• Mo XD, Zhang XH, Xu LP, et al. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol. 2016b;96:297–308.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003–4011.
   PubMed Web of Science ®Google Scholar
• Jacoby E, Chen A, Loeb DM, et al. Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016;22(1):112–118.
   PubMed Web of Science ®Google Scholar
• Elmariah H, Kasamon YL, Zahurak M, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transplant. 2018 May;24(5):1099–1102.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Karmali R, Rocha V, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34(26):3141–3149.
   PubMed Web of Science ®Google Scholar
• Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–947.
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Kasamon YL, Kanakry CG, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102(2):391–400.
   PubMed Web of Science ®Google Scholar
• Finke J, Schmoor C, Bethge WA, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4(6):e293–e301.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–1496.
   PubMed Web of Science ®Google Scholar
• Palmer J, Chai X, Martin PJ, et al. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica. 2015;100(5):690–695.
   PubMed Web of Science ®Google Scholar
• Hill L, Alousi A, Kebriaei P, et al. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol. 2018 Jan;9(1):21–46.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–2579.
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13–21.
   PubMed Web of Science ®Google Scholar
• Cooke KR, Luznik L, Sarantopoulos S. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;2:211–234.
   Google Scholar
• Wolff D, Greinix H, Lee SJ, et al. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplant. 2018;53(7):832–837.
   PubMed Web of Science ®Google Scholar
• Abboud I, Porcher R, Robin M, et al. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1251–1257.
   PubMedGoogle Scholar
• Martin PS, Li S, Nikiforow S, et al. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016;101:499–505.
   PubMed Web of Science ®Google Scholar
• Nakasone H, Tian L, Sahaf B, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood. 2015;125:3193–3201.
   PubMed Web of Science ®Google Scholar
• Oudin C, Chevallier P, Furst S, et al. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica. 2014;99:1762–1768.
   PubMed Web of Science ®Google Scholar
• Pichler H, Fritsch G, König M, et al. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter? Br J Haematol. 2016;173:905–917.
   PubMed Web of Science ®Google Scholar
• Romee R, Weisdorf DJ, Brunstein C, et al. Impact of ABO-mismatch on risk of graft-versus-host disease after umbilical cord blood transplantation. Bone Marrow Transplant. 2013;48:1046–1049.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu DH, Fan ZP, et al. Prevention of relapse using DLI can increase survival following HLA‐identical transplantation in patients with advanced‐stage acute leukemia: a multi‐center study. Clin Transplant. 2012;26:635–643.
   PubMed Web of Science ®Google Scholar
• Wun CM, Piao Z, Hong KT, et al. Effect of donor STAT4 polymorphism rs7574865 on clinical outcomes of pediatric acute leukemia patients after hematopoietic stem cell transplant. Int Immunopharmacol. 2017;43:62–69.
   PubMed Web of Science ®Google Scholar